A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Conditions
Narcolepsy Type 1
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Alkermes Investigational Site, Cullman, Alabama, United States
Alkermes Investigational Site, Los Angeles, California, United States
Alkermes Investigational Site, Boulder, Colorado, United States
Alkermes Investigational Site, Brandon, Florida, United States
Alkermes Investigational Site, Miami, Florida, United States
Alkermes Investigational Site, Winter Park, Florida, United States
Alkermes Investigational Site, Macon, Georgia, United States
Alkermes Investigational Site, Kansas City, Kansas, United States
Alkermes Investigational Site, Newton, Massachusetts, United States
Alkermes Investigational Site, Lansing, Michigan, United States
Alkermes Investigational Site, St Louis, Missouri, United States
Alkermes Investigational Site, Middletown, New Jersey, United States
Alkermes Investigational Site, Cincinnati, Ohio, United States
Alkermes Investigational Site, Wyomissing, Pennsylvania, United States
Alkermes Investigational Site, Columbia, South Carolina, United States
Alkermes Investigational Site, Austin, Texas, United States
Alkermes Investigational Site, San Antonio, Texas, United States
Alkermes Investigational Site, Sugar Land, Texas, United States
Alkermes Investigational Site, Macquarie Park, New South Wales, Australia
Alkermes Investigational Site, Markham, Ontario, Canada
Alkermes Investigational Site, Toronto, Ontario, Canada
Alkermes Investigational Site, Zwolle, Overijssel, Netherlands
Study leads
Medical Director, MD
Study Director
Alkermes, Inc.